NeurovascularMedicine.com
MEDICAL DISCLAIMER:The contents are under continuing development and improvements and despite all efforts may contain errors of omission or fact. This is not to be used for the assessment, diagnosis or management of patients. It should not be regarded as medical advice by healthcare workers or laypeople. It is for educational purposes only. Please adhere to your local protocols. Use the BNF for drug information. If you are unwell please seek urgent healthcare advice. If you do not accept this then please do not use the website.









Rivaroxaban


Learning objectives

  • Learning
  • Understand
  • Integrate
  • Reflect

Indicated in non rheumatic AF with one of the following previous stroke or transient ischaemic attack, CCF, age > 75 years, diabetes mellitus or hypertension

About : Always check the BNF link here
  • Prevent stroke/systemic embolism in non valvular AF with additional risk factor
  • Check BNF or equivalent for uptodate prescribing advice
  • Alternative to Warfarin - approximately £3 per day
Action
  • Clots are formed by fibrin from fibrinogen
  • It is a direct factor Xa inhibitor
  • Targets free and clot-bound Factor Xa in the prothrombinase complex
  • Half life about 12 hours and 66% renal excretion
Indications
  • Non valvular AF: For patients with CrCl >50 mL/min: 20 mg PO OD with the evening meal, For patients with CrCl 15 - 50 mL/min: 15 mg PO OD with the evening meal
  • VTE prophylaxis: Following knee replacement surgery Rivaroxaban 10 mg OD for 2 weeks, to be started 6-10 hours after surgery.
  • VTE prophylaxis: Following hip replacement surgery: Rivaroxaban 10 mg OD for 5 weeks, to be started 6-10 hours after surgery.
  • DVT and PE: Rivaroxaban 15 mg BD for 21 days, to be taken with food. then 20 mg once daily. Some may need only 15 mg OD.
  • ACS: Rivaroxaban 2.5 mg BD usually for 12 months
Interactions
  • Increased bleed risk with Aspirin, P2Y12 platelet inhibitors, other anti -thrombotic agents, fibrinolytic therapy, and NSAID
  • Avoid with Cytochrome P450 3a4 Inducers: carbamazepine, phenytoin, rifampicin, St. John's wort
  • Avoid with Cytochrome P450 3a4 Inhibitors: Ketoconazole, ritonavir, Clarithromycin, Erythromycin and Fluconazole
Cautions
  • Renal failure, Liver disease
Contraindications
  • Renal failure, Active pathological bleeding, Severe hypersensitivity reaction
  • Significant risk of major bleeding: GI ulcer, oesophageal varices
  • Recent brain, spine, or ophthalmic surgery
  • Recent intracranial haemorrhage, malignant neoplasms, vascular aneurysm
Side effects
  • Bleeding, falls, abdominal pain, Nausea, Vomiting, Headache, Constipation